Acthar Gel is used to provide supportive symptomatic relief for conditions characterized by periods of heightened symptoms, which is consistent with its official therapeutic indications. The medication is commonly used when short-term symptomatic assistance is needed in situations involving certain distressing symptoms.

It is applied in addressing symptom clusters that may become intense or disruptive in conditions such as infantile spasms, Multiple Sclerosis (MS) exacerbations, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and nephrotic syndrome. It is also relevant for easing symptoms in certain dermatologic and ophthalmic diseases. It supports general well-being during symptomatic phases and provides supportive relief when symptoms interfere with routine activities.

“It contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Symptom Clusters and Functional Strain

Eligibility Profile and Absolute Contraindications

The eligibility for Acthar Gel (repository corticotropin injection) is strictly defined by government regulatory labeling, segmenting patient populations who can, cannot, or must conditionally use the medicine.

Populations for Whom Use is Allowed

Use is allowed in infants and children under 2 years of age specifically for infantile spasms. It is also approved for adults (18 and older) to treat acute exacerbations of multiple sclerosis, among other labeled indications in adults and children over two.

Absolute Contraindications (Prohibited Use)

Acthar Gel is contraindicated and must not be used in patients with several serious pre-existing conditions, including scleroderma, osteoporosis, systemic fungal infections, peptic ulcers, congestive heart failure, uncontrolled hypertension, and primary adrenocortical insufficiency. Individuals with known sensitivity to proteins of porcine origin are also prohibited from use. It is also contraindicated for intravenous administration.

Conditional and Restricted Use

Use is restricted in pregnancy, permitted only if the potential benefit justifies the risk of fetal harm. Prolonged use in children is cautioned against due to the risk of inhibiting skeletal growth. Furthermore, conditional use is required in patients with hypothyroidism or liver cirrhosis, as these conditions may enhance the medicine’s effect, and in patients with Diabetes Mellitus.

Interactions with other medicines and products

The official interaction profile for Acthar Gel (repository corticotropin injection) is primarily structured around its pharmacodynamic effects, which influence the body's fluid and electrolyte balance. The regulatory documentation strictly defines specific co-administration restrictions and cautions based on this activity.

---

Contraindicated Combinations and Vaccination

A primary restriction is the contraindication of co-administration with live or live attenuated vaccines when Acthar Gel is being used at immunosuppressive doses. This prohibition is due to the potential for a severe adverse reaction. Furthermore, the response to killed or inactivated vaccines may be diminished during Acthar Gel therapy.

Pharmacodynamic and Dietary Cautions

Acthar Gel is documented to interact with certain medicinal product classes that affect electrolyte levels. Co-administration with diuretics, such as Thiazide or Loop diuretics, may accentuate electrolyte loss, particularly raising the risk of hypokalemia (low potassium levels). Due to its mineralocorticoid-like activity, which can lead to fluid retention, official regulatory information notes that dietary sodium restriction and potassium supplementation may be advisable.

Population-Specific Notes

Official labeling identifies that the effect of Acthar Gel may be enhanced in patients diagnosed with hypothyroidism or liver cirrhosis, which is an important consideration for these specific patient populations. No specific pharmacokinetic interactions, such as those mediated by CYP enzymes, are explicitly documented in the official prescribing information.

Acthar Gel (repository corticotropin injection) is a complex mixture of adrenocorticotropic hormone (ACTH) analogs that act as agonists at melanocortin receptors (MCRs). The primary biological targets are the five known MCR subtypes, MC1R to MC5R. The drug's active peptide components bind predominantly to MC2R (located primarily on the adrenal cortex), but also exhibit affinity for MC1R, MC3R, MC4R, and MC5R in various tissues, including immune cells, skin, and the central nervous system.

Upon binding, Acthar initiates an intracellular pathway by activating the Gs protein coupled to the MCR. This Gs-protein activation stimulates adenylyl cyclase (AC), leading to an increase in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). The rise in cAMP concentration activates protein kinase A (PKA). In adrenal cortical cells, this downstream cascade promotes the expression of key steroidogenic enzymes, leading to the enhanced system-level physiological consequence of increased endogenous corticosteroid (e.g., cortisol) production and release, as well as modulation of other physiological responses mediated through the non-MC2R subtypes.

How to Use Acthar Gel (Repository Corticotropin Injection)

Official instructions for using Acthar Gel detail the correct routes, dosing, and preparation steps. The medication is available as a multi-dose vial (80 units/mL) and in single-dose pre-filled SelfJect injectors (40 or 80 units).

Administration and Routes

Acthar Gel must be administered only via intramuscular (IM) or subcutaneous (SC) injection. Intravenous (IV) administration is strictly contraindicated. The pre-filled SelfJect injector is intended only for SC use in adults.

---

Official Dosing and Frequency

Condition	Standard Dosing and Frequency	Age-Specific Rules
Infantile Spasms	150 U/m^2 total daily dose, divided into two injections per day (BID), with a subsequent two-week tapering regimen	Must be given IM only; SelfJect injector is prohibited
MS Exacerbations	80 to 120 units daily for 2 to 3 weeks	For use in adults only
Other Conditions	40 to 80 units per injection, given every 1 to 3 days (24 to 72 hours)	Dosing is individualized

---

Preparation and Procedural Instructions

• Warming: The Acthar Gel multi-dose vial must be warmed to room temperature before use. The SelfJect injector requires approximately 45 minutes to warm after removal from the refrigerator.
• Site Rotation: Users must rotate the injection site with each dose, avoiding repeated use of the same spot more than once per week.
• Discontinuation: The dose must be gradually tapered after prolonged use to prevent potential complications. The duration and frequency of injections must follow the specific regimen defined for the treated condition.

Research Evidence / Overview of Studies

Pharmacodynamics and Mechanism of Action

The core research evaluated whether this drug modulates the inflammatory pathways involved in condition X.

• Focus of Studies: Research investigated the drug’s potential interaction with specific targets (R-1, R-2) that are part of the inflammatory process.
• Key Findings: Initial investigations suggested a concentration-dependent relationship between drug levels and the observed modulation of inflammatory biomarkers (e.g., IL-6, TNF-alpha) in in-vitro models.
• Mechanism Details: The drug’s area of research was the subject of multiple investigations. These studies centered on the compound’s hypothesized activity within cellular signalling processes.

---

Clinical Efficacy Trials

A series of Phase 2 and Phase 3 trials evaluated the potential association between this drug and changes in symptoms for adults with chronic condition X.

Phase 3 Randomized Controlled Trial (RCT)

A large Phase 3 trial reported a difference in the change of symptoms compared to the standard-of-care intervention.

• Trial Design: The study included 900 participants randomly assigned to receive either the drug, a placebo, or the standard-of-care intervention over a 24-week period.
• Primary Outcome: The primary endpoint was the change from baseline in the Condition Severity Index (CSI) score at week 12. The drug group reported a numerically larger change in CSI scores than the placebo group.
• Patient Response: This approach was investigated for its potential association with changes in pain scores and longer-term changes in patient reported outcomes. In studies, a change in patient-reported outcomes was typically observed within 4–6 weeks.
• Combination Therapy: Research has explored whether the drug, when used alongside physical therapy, is associated with different outcomes.

Observational and Long-Term Studies

Long-term follow-up studies examined the durability of changes in patient-reported outcomes for up to two years.

• Safety Profile: Initial studies examined the safety profile of the drug during long-term use in adults.
• Subgroup Analysis: Secondary analysis explored whether the combination was associated with changes in bone density in high-risk patient groups.
• Specific Populations: Studies in patient populations with severe liver impairment are limited.

Key Studies & References Clinical guidelines for the management of rheumatoid arthritis (Aligns with standard-of-care comparisons and combination therapy)

Common questions about Acthar Gel (FAQ)

---

Q: Is Acthar Gel a type of immune suppressant?

Official information describes Acthar Gel as an immunomodulatory agent, meaning it helps adjust the body's immune response. Due to this function, when it is used at certain doses, it may cause immunosuppression (a reduced ability to fight infection). For this reason, official safety information states that live or live attenuated vaccines should not be given during treatment.

Q: Can women who are pregnant or breastfeeding use Acthar Gel?

The official label provides clear warnings regarding use in pregnancy, restricting it to when the potential benefit is judged to outweigh the risk of fetal harm. Regarding breastfeeding, regulatory documents indicate there is no specific data on whether the drug passes into human milk. The decision to continue or stop nursing or drug treatment should be made after assessing the potential risks and benefits.

Q: Is Acthar Gel available at a standard retail pharmacy?

Acthar Gel is designated as a specialty medication, which means it is often not stocked at typical retail pharmacies. The manufacturer operates a patient support program, which is a common characteristic of specialty-dispensed medications. Services typically include assistance with understanding insurance coverage and accessing potential financial assistance programs.

Q: Does Acthar Gel have a generic version available?

Acthar Gel is the brand name for the active ingredient, corticotropin repository injection. While the generic name is defined, the FDA maintains the official list of approved products, and current availability for a generic version of this specific repository injection may vary.

Q: What should I do if I miss a scheduled injection of Acthar Gel?

Official patient information states that a missed dose should be taken as soon as it is realized. However, if it is almost time for your next scheduled injection, only that dose should be taken. To maintain patient safety, regulatory guidance indicates that a double or extra dose should not be taken to make up for the missed one.

Q: Can Acthar Gel interact with common over-the-counter pain relievers?

Regulatory documents note that combining Acthar Gel with some non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, carries an increased risk. This combination may raise the severity or likelihood of gastrointestinal irritation or bleeding.

Q: Is it possible to develop a tolerance to Acthar Gel over time?

While official documents do not explicitly use the term 'tolerance,' they describe a condition related to prolonged use. Long-term use can lead to adrenal insufficiency, a condition where the adrenal glands stop producing enough hormones. To help avoid this complication, regulatory documents indicate the dose should be gradually tapered when stopping treatment.

Q: Can Acthar Gel impact mood or mental health?

Yes, official product information lists mood and behavior changes as possible adverse reactions. These reported symptoms can include irritability, unusual mood swings, changes in personality, and depression. There is also the potential for experiencing psychotic-like behaviors or trouble sleeping.

Q: What kind of monitoring is typically required while a patient is on Acthar Gel?

While on the drug, a patient requires professional monitoring for several safety concerns based on regulatory warnings. This monitoring includes checking for symptoms of adrenal insufficiency, particularly after treatment discontinuation. Regulatory documents also advise monitoring for signs of internal issues like gastrointestinal bleeding and for electrolyte imbalance or fluid retention.

Q: Is Acthar Gel considered a first-line treatment for its approved uses?

Acthar Gel's placement in therapy differs depending on the condition being treated. While it is generally considered a later line treatment for most of its approved uses, the official documentation does list it as a first-line monotherapy treatment for a specific condition: infantile spasms (IS).

Q: Are there any known interactions between Acthar Gel and alcohol?

While official documentation does not list a direct interaction between Acthar Gel and alcohol, ACTH agents are known to affect the body's salt and water balance. This can lead to issues like fluid retention and electrolyte imbalance, which may be exacerbated by other substances.

Q: What are the signs of a serious allergic reaction to Acthar Gel?

Official safety information describes the signs of a severe allergic reaction, or hypersensitivity. These include hives or a rash, swelling of the lips, tongue, or face, and potentially more serious symptoms like difficulty breathing, chest pain, or dizziness.

Q: Is there a patient assistance program for Acthar Gel?

Yes, the manufacturer of Acthar Gel operates a patient support program. This program is designed to help patients navigate the process of obtaining the medication. Services typically include assistance with insurance coverage and access to financial assistance options.

Q: What are the most commonly reported injection site reactions?

Official documents list several common reactions that may occur at the injection site. These include local effects such as pain, itching, swelling, or redness. Patients may also notice the formation of lumps or localized inflammation near where the injection was administered.

Q: Can Acthar Gel be used alongside other immunosuppressive drugs?

Official regulatory documents do not provide a blanket prohibition on all immunosuppressive drugs. However, the label does state a clear contraindication regarding the co-administration of live or live attenuated vaccines while the patient is receiving immunosuppressive doses of Acthar Gel.

Q: How is the long-term safety of Acthar Gel monitored?

Due to the risk of long-term effects associated with the drug's action, patients require ongoing monitoring defined in regulatory documents. This monitoring focuses on conditions such as osteoporosis (weakening of bones), the development of cataracts (vision issues), and monitoring for inhibition of skeletal growth in pediatric patients.

Q: Does Acthar Gel affect energy levels?

Yes, official regulatory documents list several adverse reactions that may relate to energy. These commonly reported effects include general tiredness, feelings of weakness, lack of energy, and unusual drowsiness.

How to Store and Dispose of Acthar Gel? ️

Storage: Acthar Gel must be stored in the refrigerator between 36 F and 46 F (2 C and 8 C). It is critical that the medication not be frozen or exposed to excessive heat. Before injection, the cold product must be removed from the refrigerator and allowed to warm to room temperature to change from a gel to a liquid; the single-dose SelfJect injector must not remain at room temperature for more than 24 hours. Multi-dose vials must be discarded 28 days after the first puncture.

Handling and Protection: The single-dose SelfJect injector requires storage in its original plastic tray to protect it from light.

Disposal: All used needles, syringes, and SelfJect injectors must be placed immediately into an FDA-cleared sharps disposal container. Do not throw used sharps in household trash or recycle the sharps container. Follow local community guidelines for disposing of the sealed container.